S. Nicole Schaeffer Orlov, Chief People Strategy Officer of Insmed Incorporated, filed a Form 4 on November 20, 2026, reporting multiple stock option exercises and open-market sales of common stock executed on November 19, 2026, under a Rule 10b5-1 trading plan.
Key Highlights
- Options exercised: Schaeffer Orlov exercised 55,400 stock options at $30.46 per share and 45,700 stock options at $26.43 per share, both on November 19, 2026.
- Shares sold: A total of 101,100 shares were disposed of across three separate sale transactions at weighted average prices of $145.06, $146.76, and $147.50 per share.
- Remaining ownership: Following all reported transactions, Schaeffer Orlov directly beneficially owned 41,895 shares of common stock.
- 10b5-1 plan: All transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2026.
- Derivative securities: Both stock option positions were reduced to zero following the exercises, with the underlying options carrying expiration dates of January 4, 2028, and January 6, 2032, respectively.
- ESPP shares: The beneficial ownership figure of 97,295 shares reported after the first option exercise includes 141 shares acquired through the company's 2018 Employee Stock Purchase Plan.
Schaeffer Orlov's November 19 Option Exercises and Share Sales at Insmed
According to the filing, S. Nicole Schaeffer Orlov, identified as Chief People Strategy Officer of Insmed Incorporated (NASDAQ:INSM), reported a series of transactions on November 19, 2026. She exercised two stock option grants: 55,400 options with an exercise price of $30.46 per share, originally expiring January 4, 2028, and 45,700 options with an exercise price of $26.43 per share, originally expiring January 6, 2032. The filing states that both option positions were fully exercisable at the time of the transactions, having vested on a schedule of 25% on the first anniversary of the grant date and an additional 12.5% on each six-month anniversary thereafter through the fourth anniversary.
Following the exercises, the filing discloses three separate open-market sale transactions. The largest involved 90,299 shares sold at a weighted average price of $145.06, with individual sale prices ranging from $145.00 to $145.93 per share. A second sale covered 8,539 shares at a weighted average price of $146.76, with prices ranging from $146.10 to $147.09. A third sale of 2,262 shares occurred at a weighted average price of $147.50, with prices ranging from $147.38 to $148.01. The reporting person undertook to provide per-price breakdowns to the SEC, the issuer, or any security holder upon request.
The filing states that all transactions were made pursuant to a 10b5-1 trading plan that Schaeffer Orlov adopted on May 11, 2026. After all reported activity, her direct beneficial ownership stood at 41,895 shares of Insmed common stock, according to the filing.
What Was Disclosed
Schaeffer Orlov's Form 4 disclosed the exercise of two stock option grants totaling 101,100 shares and the subsequent sale of 101,100 shares of Insmed common stock on November 19, 2026, all conducted under a pre-established Rule 10b5-1 trading plan.



Please wait processing your request...